J. Lim

PAM-1616, a selective peroxisome proliferator-activated receptor γ modulator with preserved anti-diabetic efficacy and reduced adverse effects.

Mi-kyung Kim, M. Son, J. G. Kim, 2011, European journal of pharmacology.

Anti-diabetic effects of DA-11004, a synthetic idpc inhibitor in high fat high sucrose Diet-Fed C57BL/6J mice

T. Huh, M. Son, Won Bae Kim, 2004, Archives of pharmacal research.

PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.

Mi-kyung Kim, M. Son, Mi-Kyung Kim, 2008, European journal of pharmacology.

PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention

Mi-kyung Kim, M. Son, J. G. Kim, 2009, Archives of pharmacal research.